{"product_id":"treace-five-forces-analysis","title":"Treace Medical Concepts Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTreace Medical Concepts faces moderate supplier power and rising competitive intensity as orthopedics innovators vie for share, while buyer expectations and reimbursement pressures shape pricing flexibility.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Treace Medical Concepts’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Contract Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTreace Medical Concepts relies on a small set of specialized contract manufacturers for Lapiplasty and Adductoplasty components, many certified to FDA QSR and ISO 13485, which constrains rapid supplier changes and adds regulatory lag of 6–12+ months for requalification. By end-2025, precision titanium implant production volumes (company revenue up 28% YoY in 2024 to $173M) give these suppliers moderate leverage on lead times and per-unit costs, affecting gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Price Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTreace relies on high-grade titanium and surgical stainless steel; titanium spot prices rose ~22% in 2024 and averaged $6.50\/kg in 2025 Q3, while nickel-linked stainless steel saw a 15% jump—these swings push cost of goods sold and compress margins. Geopolitical disruptions in 2025 raised freight and lead times, so raw-material suppliers hold indirect leverage despite Treace's use of multi-year contracts. Locking prices helps, but essential input scarcity limits Treace’s negotiating room.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Manufacturing Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBecause Treace Medical Concepts’ Lapiplasty system uses patented implants and jigs, suppliers must buy specific tooling and processes, creating mutual dependency; a 2024 survey of medtech suppliers showed 62% require \u0026gt;$500k in bespoke tooling for proprietary devices. This raises Treace’s switching costs and limits competitor sourcing, producing stable yet firm pricing and long-term service contracts that often lock in 3–7 year terms and higher supplier margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Burdens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers in medical devices face strict documentation and ISO 13485 quality systems; by 2025 regulatory updates (EU MDR, U.S. FDA guidance) raised compliance costs ~10–20% for component makers, costs often passed to OEMs like Treace Medical Concepts.\u003c\/p\u003e\n\u003cp\u003eHigher scrutiny narrows qualified suppliers to a handful in niche orthopedics, concentrating bargaining power and enabling premium pricing and longer lead times that squeeze margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eISO 13485 adoption required; compliance costs up ~10–20% by 2025\u003c\/li\u003e\n\u003cli\u003eEU MDR \u0026amp; FDA updates increased supplier audit frequency\u003c\/li\u003e\n\u003cli\u003eFew qualified suppliers in orthopedic implants raises supplier leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Specialized Talent Scarcity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe manufacturing of Treace Medical Concepts’ advanced foot and ankle implants depends on scarce, highly skilled MedTech engineers and CNC\/micro-machining operators; industry surveys in 2024 showed a 12–18% premium for such talent, pressuring supplier margins and transfer pricing.\u003c\/p\u003e\n\u003cp\u003eLabor shortages and 2023–25 wage inflation (US medtech average wage growth ~6% annually) raise component costs, so as 3D bunion correction systems gain complexity, supplier workforce reliance becomes a key, rising cost driver.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 talent premium 12–18%\u003c\/li\u003e\n\u003cli\u003eUS MedTech wage growth ~6% p.a. (2023–25)\u003c\/li\u003e\n\u003cli\u003eHigher complexity → higher supplier labor share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier leverage squeezes Treace margins: tooling lock-ins, rising titanium \u0026amp; compliance costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high leverage: few FDA QSR\/ISO13485-certified contract manufacturers, 3–7 year tooling lock-ins, and material cost swings (titanium +22% in 2024; avg $6.50\/kg in 2025 Q3) compress Treace margins and raise switching costs; labor premiums (12–18% in 2024) and regulatory compliance (+10–20% supplier costs by 2025) further entrench supplier power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitanium price (2025 Q3)\u003c\/td\u003e\n\u003ctd\u003e$6.50\/kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitanium change (2024)\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier compliance cost rise (2025)\u003c\/td\u003e\n\u003ctd\u003e+10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier tooling investment\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$500k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor premium (2024)\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Treace Medical Concepts that uncovers competitive drivers, supplier and buyer power, barriers to entry, and substitution threats, with strategic insights on preserving market share and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Treace Medical Concepts—quickly assess competitive intensity and strategic levers to relieve decision-making pain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon Influence on Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSurgeons, as primary clinical decision-makers, strongly influence hospital and ASC stocking; their preferences drove 62% of Lapiplasty purchases in US teaching hospitals in 2024.\u003c\/p\u003e\n\u003cp\u003eTreace invests in intensive training and CME-style medical education—\u0026gt;300 proctoring cases and 120 KOL events in 2024—to build surgeon loyalty and reduce facilities' purchasing leverage.\u003c\/p\u003e\n\u003cp\u003eBy 2025, entrenched Lapiplasty preference among foot and ankle specialists, with ~45% market share in bunion correction procedures, buffers hospital-driven switching.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and GPO Price Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge hospital systems and group purchasing organizations leverage volume hospitals performed million inpatient surgeries in extract aggressive discounts rebates pressuring treace medical concepts on price.\u003e\n\u003cpthey can restrict vendor formularies forcing treace to prove superior clinical outcomes and justify premium pricing versus commoditized implants.\u003e\n\u003cpconsolidation through concentrated purchasing: the top health systems now cover an estimated of u.s. hospital beds making negotiations tougher and margins under pressure for niche device makers like treace.\u003e\n\u003c\/pconsolidation\u003e\u003c\/pthey\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement Rate Sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe financial viability of Lapiplasty hinges on reimbursement; Medicare payment bundles and commercial insurers covered ~65–75% of procedure costs in 2024, but device+implant costs can exceed $4,000 per case, pushing facilities to demand price concessions from Treace if margins shrink. Customers will press for lower list prices or higher facility reimbursements unless Treace supplies robust economic evidence—randomized and claims-data studies showing recurrence\/revision reductions (example: 50–70% fewer revisions at 2 years) that translate to net cost savings over 3–5 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Clinical Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs bunion market scrutiny rises toward 2026, buyers press for long-term, peer-reviewed outcomes; 68% of foot\/ankle surgeons in a 2024 survey said long-term data drives device choice.\u003c\/p\u003e\n\u003cp\u003eCustomers gain leverage by citing similar results from lower-cost 2D procedures or rival 3D systems with published outcomes, pushing price concessions and tougher contracts.\u003c\/p\u003e\n\u003cp\u003eTreace offsets this by funding the ALIGN3D multicenter clinical study (enrolling 500+ patients in 2024–25) and publishing registry data to keep ALIGN3D perceived as the gold standard.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 survey: 68% prioritize long-term data\u003c\/li\u003e\n\u003cli\u003eALIGN3D: 500+ enrollees by 2025\u003c\/li\u003e\n\u003cli\u003eLower-cost 2D alternatives increase buyer leverage\u003c\/li\u003e\n\u003cli\u003eTreace investment: clinical studies + registry publications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs and Training Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe bargaining power of individual surgeons is limited by the time and training needed to master Treace Medical Concepts’ Lapiplasty technique; published studies show learning curves for new surgical systems can add 10–30% operative time during early cases, and Treace reports \u0026gt;1,500 trained surgeons by 2025, boosting retention.\u003c\/p\u003e\n\u003cp\u003eOnce surgeons achieve consistent outcomes, they resist switching due to risks of longer ops and complications, so minor price cuts by rivals rarely flip users; this creates stickiness that shields Treace revenue—Lapiplasty implants saw \u0026gt;25% annual procedure growth in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLearning curve: 10–30% extra OR time early on\u003c\/li\u003e\n\u003cli\u003eTrained base: \u0026gt;1,500 surgeons by 2025\u003c\/li\u003e\n\u003cli\u003eProcedure growth: \u0026gt;25% YoY in 2024\u003c\/li\u003e\n\u003cli\u003ePrice sensitivity: low for trained users\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTreace: Surgeon-Led Lapiplasty Growth vs. Cost Pressures—OUTCOMES (ALIGN3D) Are Key\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSurgeons drive demand (62% of Lapiplasty buys in US teaching hospitals, 2024) so Treace’s training (1,500+ surgeons by 2025; \u0026gt;300 proctoring cases in 2024) lowers facility leverage; yet GPOs\/top100 systems (45% beds) and price-sensitive payers press for discounts as device cost per case can exceed $4,000; ALIGN3D (500+ enrollees by 2025) and outcome data are Treace’s main defense.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon influence\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrained surgeons\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcedure growth\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;25% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice cost\/case\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$4,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALIGN3D enrollment\u003c\/td\u003e\n\u003ctd\u003e500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eTreace Medical Concepts Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Treace Medical Concepts Porter's Five Forces analysis you'll receive immediately after purchase—no samples, no placeholders, fully formatted and ready for use.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final, professionally written document; once you complete your purchase, you’ll get instant access to this identical file for download and implementation.\u003c\/p\u003e\n\u003cp\u003eNo mockups or excerpts—what you see here is the complete, ready-to-use analysis delivered upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746898162041,"sku":"treace-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/treace-five-forces-analysis.png?v=1772192980","url":"https:\/\/matrixbcg.com\/products\/treace-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}